Serum N-terminal pro-B-type natriuretic peptide levels are associated with left atrial dilation, resting left ventricular outflow tract gradient, and pulmonary hypertension in patients with hypertrophic cardiomyopathy
暂无分享,去创建一个
[1] A. Baranchuk,et al. E/eʹ ratio and left atrial area are predictors of atrial fibrillation in patients with hypertrophic cardiomyopathy , 2018, Echocardiography.
[2] A. Kubik,et al. Circulating biomarkers of hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy assessed by cardiac magnetic resonance , 2018, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[3] S. Y. Wang,et al. [Value of N-terminal pro-B-type natriuretic peptide on long-term outcome of patients with hypertrophic cardiomyopathy]. , 2018, Zhonghua xin xue guan bing za zhi.
[4] P. Dimitrow,et al. Elevated Level of Troponin but Not N-Terminal Probrain Natriuretic Peptide Is Associated with Increased Risk of Sudden Cardiac Death in Hypertrophic Cardiomyopathy Calculated According to the ESC Guidelines 2014 , 2017, Disease markers.
[5] Shuiyun Wang,et al. Time and age dependent decrease of NT-proBNP after septal myectomy in hypertrophic obstructive cardiomyopathy , 2017, Clinical chemistry and laboratory medicine.
[6] P. Petkow Dimitrow,et al. Associaton of elevated troponin levels with increased heart rate and higher frequency of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy. , 2017, Polish archives of internal medicine.
[7] R. Siegel,et al. Clinical utility of natriuretic peptides and troponins in hypertrophic cardiomyopathy. , 2016, International journal of cardiology.
[8] P. Dimitrow,et al. Obstructive Form of Hypertrophic Cardiomyopathy-Left Ventricular Outflow Tract Gradient: Novel Methods of Provocation, Monitoring of Biomarkers, and Recent Advances in the Treatment , 2016, BioMed research international.
[9] S. Qiao,et al. Predictive Values of N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin I for Myocardial Fibrosis in Hypertrophic Obstructive Cardiomyopathy , 2016, PloS one.
[10] A. Anastasakis,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.
[11] J. Veselka,et al. Low incidence of procedure-related major adverse cardiac events after alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy. , 2013, The Canadian journal of cardiology.
[12] G. Gensini,et al. Prognostic value of N-terminal pro-brain natriuretic Peptide in outpatients with hypertrophic cardiomyopathy. , 2013, The American journal of cardiology.
[13] A. Dawnay,et al. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. , 2013, European heart journal.
[14] D. Sorysz,et al. Left Ventricular Outflow Tract Gradient Provoked by Upright Position or Exercise in Treated Patients with Hypertrophic Cardiomyopathy without Obstruction at Rest , 2009, Echocardiography.
[15] Z. Kornacewicz-Jach,et al. Alcohol septal ablation in hypertrophic cardiomyopathy utilizing a longitudinal 17-year study (mean 10.8). Observation follow-ups taken at a single medical centre. , 2017, Cardiology journal.
[16] A. Dawnay,et al. Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease. , 2013, The American journal of cardiology.